Literature DB >> 8759981

Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis.

S R Schwid1, A D Goodman, J E Puzas, M P McDermott, D H Mattson.   

Abstract

BACKGROUND: Bone mineral density is reduced in patients with multiple sclerosis (MS), but the reduction has not been shown to correlate with steroid use retrospectively.
OBJECTIVE: To prospectively measure bone density following a single corticosteroid pulse using dual energy x-ray absorptiometry. PATIENTS AND METHODS: Thirty acutely relapsing patients with MS were given 1000 mg of methylprednisolone intravenously daily for 3 days followed by an oral prednisone taper for 2 weeks. The bone density was determined at the lumbar spine and femoral neck prior to treatment. Seventeen patients were reevaluated 2,4, and 6 months following treatment.
RESULTS: Prior to treatment, bone density in patients with MS was already reduced at the femoral neck compared with an age-matched reference population, but the degree of this reduction did not correlate with prior steroid exposure. Lumbar density, in contrast, was normal. Following the steroid pulse, lumbar bone density increased, becoming 1.7% greater than baseline 6 months later (P = .02). Femoral bone density did not change on average, but the patients who required a cane or walker for ambulation had a 1.6% decrease in femoral bone density, while those with better ambulation had a 2.9% increase (P = .04).
CONCLUSIONS: Bone density is decreased in MS. A single corticosteroid pulse did not reduce bone density in fully ambulatory patients with MS and multiple pulses did not have a cumulative effect on bone density in retrospective analysis. The change in femoral density in poorly ambulatory patients may have been related to inactivity rather than the steroid pulse.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8759981     DOI: 10.1001/archneur.1996.00550080071014

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  23 in total

1.  Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.

Authors:  M H Kriel; J H Tobias; T J Creed; M Lockett; J Linehan; A Bell; R Przemioslo; J E Smithson; T N Brooklyn; W D Fraser; C S J Probert
Journal:  Osteoporos Int       Date:  2009-05-30       Impact factor: 4.507

2.  Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.

Authors:  M Shuhaibar; M J McKenna; M Au-Yeong; J M T Redmond
Journal:  Ir J Med Sci       Date:  2008-11-12       Impact factor: 1.568

Review 3.  Bone health in multiple sclerosis.

Authors:  J C Gibson; G D Summers
Journal:  Osteoporos Int       Date:  2011-05-21       Impact factor: 4.507

4.  Effects of high doses of corticosteroids on bone metabolism.

Authors:  P Ardissone; E Rota; L Durelli; P Limone; G C Isaia
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

Review 5.  Exercise and multiple sclerosis.

Authors:  Lesley J White; Rudolph H Dressendorfer
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

Review 6.  Treatment of acute relapses in multiple sclerosis.

Authors:  Regina Berkovich
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 7.  Choosing drug therapy for multiple sclerosis. An update.

Authors:  B W van Oosten; L Truyen; F Barkhof; C H Polman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 8.  Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions.

Authors:  Sahil Gupta; Irfan Ahsan; Naeem Mahfooz; Noureldin Abdelhamid; Murali Ramanathan; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

9.  Body composition in multiple sclerosis.

Authors:  Y Dionyssiotis
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

10.  Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis.

Authors:  Linn Hofsøy Steffensen; Svein Ivar Mellgren; Margitta T Kampman
Journal:  J Neurol       Date:  2009-10-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.